The introduction into clinical practice of the so-called second generation antidepressants has improved the treatment of depression, since these drugs, compared to the first generation antidepressants (such as imipramine and clomipramine), show a more favourable safety profile with respect to cardiovascular effects, whilst maintaining efficacy. Nevertheless, patients treated with these newer antidepressants can present undesired effects, including serotonin syndrome, sedation, body weight changes, sexual dysfunction and suicidal ideation. Therefore, with the aim of reducing the risk for toxic/side effects, therapeutic drug monitoring (TDM) of second generation antidepressants is advisable, particularly in case of patients under polypharmacy. During the last years, a number of methods have been developed in our Laboratory for the accurate determination of antidepressant drugs and their metabolites in plasma samples obtained from patients, including drugs belonging to different classes of second-generation antidepressants (SSRI, NaSSA, SNRI). Sertraline, together with its main metabolite N-desmethylsertraline, can be analysed in plasma samples using a method based on capillary electrophoresis with laser-induced fluorescence (LIF) detection. The method employs a 488 nm wavelength laser and a sample pre-treatment procedure consisting in solid-phase extraction followed by derivatisation with fluorescein isothiocyanate. The high selectivity obtained allows the determination of sertraline in plasma samples from patients under polypharmacy. Capillary electrophoresis with diode-array detection has been employed for the enantioselective determination of mirtazapine and its active metabolite N-desmethylmirtazapine in human plasma. The method is quite fast: after a solid-phase extraction procedure, the electrophoretic run lasts 2.5 min. HPLC with fluorescence detection has been used for the determination of venlafaxine together with its main metabolite O-desmethylvenlafaxine, while HPLC coupled to UV detection was employed for the analysis of duloxetine in plasma of depressed patients.

Therapeutic drug monitoring of recent antidepressants in patients under polypharmacy / A. Musenga; M.A. Raggi. - STAMPA. - (2008), pp. 69-69. (Intervento presentato al convegno TDM 2008 - Therapeutic and Toxic Effects of Central Nervous System Drugs: The Importance of Drug Monitoring tenutosi a Bologna nel October, 2-3).

Therapeutic drug monitoring of recent antidepressants in patients under polypharmacy

MUSENGA, ALESSANDRO;RAGGI, MARIA AUGUSTA
2008

Abstract

The introduction into clinical practice of the so-called second generation antidepressants has improved the treatment of depression, since these drugs, compared to the first generation antidepressants (such as imipramine and clomipramine), show a more favourable safety profile with respect to cardiovascular effects, whilst maintaining efficacy. Nevertheless, patients treated with these newer antidepressants can present undesired effects, including serotonin syndrome, sedation, body weight changes, sexual dysfunction and suicidal ideation. Therefore, with the aim of reducing the risk for toxic/side effects, therapeutic drug monitoring (TDM) of second generation antidepressants is advisable, particularly in case of patients under polypharmacy. During the last years, a number of methods have been developed in our Laboratory for the accurate determination of antidepressant drugs and their metabolites in plasma samples obtained from patients, including drugs belonging to different classes of second-generation antidepressants (SSRI, NaSSA, SNRI). Sertraline, together with its main metabolite N-desmethylsertraline, can be analysed in plasma samples using a method based on capillary electrophoresis with laser-induced fluorescence (LIF) detection. The method employs a 488 nm wavelength laser and a sample pre-treatment procedure consisting in solid-phase extraction followed by derivatisation with fluorescein isothiocyanate. The high selectivity obtained allows the determination of sertraline in plasma samples from patients under polypharmacy. Capillary electrophoresis with diode-array detection has been employed for the enantioselective determination of mirtazapine and its active metabolite N-desmethylmirtazapine in human plasma. The method is quite fast: after a solid-phase extraction procedure, the electrophoretic run lasts 2.5 min. HPLC with fluorescence detection has been used for the determination of venlafaxine together with its main metabolite O-desmethylvenlafaxine, while HPLC coupled to UV detection was employed for the analysis of duloxetine in plasma of depressed patients.
2008
Proceedings of the TDM 2008 International Meeting - Therapeutic and Toxic Effects of Central Nervous System Drugs: The Importance of Drug Monitoring
69
69
Therapeutic drug monitoring of recent antidepressants in patients under polypharmacy / A. Musenga; M.A. Raggi. - STAMPA. - (2008), pp. 69-69. (Intervento presentato al convegno TDM 2008 - Therapeutic and Toxic Effects of Central Nervous System Drugs: The Importance of Drug Monitoring tenutosi a Bologna nel October, 2-3).
A. Musenga; M.A. Raggi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/64369
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact